Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063658 | 0.89 | CYP11B1 (0.46) | CYP11B1CYP11B2CYP17A1PDE2APDE10A | |
| SCHEMBL2125696 | 0.86 | PIK3CA (0.44) | CYP11B1CYP11B2CYP17A1CYP3A4PIK3CA | |
| SCHEMBL2125276 | 0.85 | PIK3CA (0.45) | CYP11B1CYP11B2PIK3CA | |
| SCHEMBL2711406 | 0.85 | PIK3CA (0.38) | CYP11B1CYP11B2PDE2APIK3CA | |
| SCHEMBL2124466 | 0.81 | CYP11B1 (0.38) | CYP11B1CYP11B2PIK3CA | |
| SCHEMBL2126073 | 0.79 | PIK3CA (0.49) | PIK3CA | |
| SCHEMBL2713014 | 0.78 | DHODH (0.42) | CYP11B1CYP11B2CYP17A1CYP3A4 | |
| SCHEMBL2711207 | 0.78 | ADORA2B (0.44) | CYP3A4CYP2C9PIK3CA | |
| SCHEMBL2712520 | 0.77 | MAPK14 (0.48) | CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL2711314 | 0.77 | PIK3CD (0.51) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | CYP11B1 1284/4885CYP11B2 1362/4885CYP17A1 2018/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | CYP11B1 1418/4885CYP11B2 1364/4885CYP17A1 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.